Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Chapter 2 The Pre-Travel Consultation Self-Treatable Conditions

For the Record: A History of the Definition & Management of Travelers’ Diarrhea

Herbert L. DuPont


Travelers’ diarrhea (TD) is defined as the passage of ≥3 unformed stools per day plus ≥1 associated enteric symptoms, such as abdominal pain or cramps, occurring in a traveler after arrival, usually in a resource-limited destination. Many colorful terms have been used for the condition according to the places where diarrhea commonly occurred, such as Aztec Two-Step, Delhi Belly, Hong Kong Dog, Montezuma’s Revenge, and the Pharaoh’s Curse.

While it was known for centuries that diarrhea and dysentery complicated armed conflicts in international settings, it wasn’t until the 1940s that diarrhea was closely correlated with international travel and relocation in tropical regions. In the 1950s, B. H. Kean from Cornell University increased awareness of the problem by studying travelers and students from the United States in Mexico. The field mushroomed in later years, when groups studied international students and travelers, expatriates, and military populations. The history of TD can be viewed in 3 time blocks.


Kean and Waters studied the risk of TD among students and travelers to Mexico and demonstrated successful disease prevention with antibiotic chemoprophylaxis, which provided the first evidence that bacterial pathogens were responsible for most illness. Chemoprophylaxis was used in a little more than one-third of US visitors to Mexico in the 1950s and 1960s and was used by the US, Australian, and British athletes competing in the Olympics in Mexico City in 1968.


Clinical and epidemiologic features of TD were described. Microbiologic studies were carried out to determine the etiology of the illness, beginning with a study published in 1970 describing a single strain of Escherichia coli as the cause of TD in British troops stationed in Aden on the Red Sea. The next year, 2 strains of E. coli isolated from American soldiers with diarrhea acquired in Vietnam were shown to be enterotoxigenic in animals and adult volunteers, and 4 years later enterotoxigenic E. coli (ETEC) was found in most cases of TD among US students studying in a language school in Mexico.

The first clear evidence that antibiotics were effective in treating TD was in 1981 when trimethoprim-sulfamethoxazole (TMP-SMX) was shown to reduce the duration of the illness in a group of travelers with TD caused by different etiologies. Placebo-controlled clinical trials then demonstrated the value of fluoroquinolones in treating TD. Regions of the tropical and semitropical world were studied, allowing scientists to categorize areas according to risk that international visitors would face of acquiring TD.

Although prophylactic antibiotics were used by international travelers at the time, in 1985 chemoprophylaxis with systemic antibiotics was strongly discouraged because of concerns about adverse drug events and development of drug resistance. The Consensus Development Panel favored self-treatment with short-course (single-dose or 3 days) antibiotics.


During this phase, the fluoroquinolones, particularly ciprofloxacin, became the mainstay of therapy for TD. The poorly absorbed (<0.4%) rifamycin antibiotic, rifaximin, was found to be as effective as ciprofloxacin for the most common TD syndrome, watery diarrhea. After more than a decade of use of fluoroquinolones for a variety of infectious disease conditions, resistance to this class of drugs has become more common among some bacterial causes of TD, particularly Campylobacter jejuni. The emergence of resistance encouraged the wider use of azithromycin, either single-dose or 3-day courses, to treat TD.

Chemoprophylaxis was once more examined with bismuth subsalicylate or rifaximin, both of which appeared to have a more acceptable safety profile and fewer concerns about resistance compared with the absorbed antibiotics. Currently, there are no general recommendations for this approach.

With the knowledge that bacterial diarrhea may be associated with the development of postinfectious irritable bowel syndrome and that bacterial enteropathogens caused most cases of TD, studies of travelers were undertaken. These small studies found that 5%–10% of people developed new-onset irritable bowel syndrome after experiencing TD in Mexico or Asia, although in most of these people, no bacterial pathogen was identified. Studies are needed to further analyze this possible association and to develop and analyze methods of prevention, which could include early therapy (with passage of the first unformed stool), antibiotic chemoprophylaxis, or a vaccine.


  1. DuPont HL, Ericsson CD, Farthing MJ, Gorbach S, Pickering LK, Rombo L, et al. Expert review of the evidence base for prevention of travelers’ diarrhea. J Travel Med. 2009 May–Jun;16(3):149–60.
  2. DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, et al. Pathogenesis of Escherichia coli diarrhea. N Engl J Med. 1971 Jul 1;285(1):1–9.
  3. DuPont HL, Jiang ZD, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001 Dec 1;33(11):1807–15.
  4. DuPont HL, Reves RR, Galindo E, Sullivan PS, Wood LV, Mendiola JG. Treatment of travelers’ diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med. 1982 Sep 30;307(14):841–4.
  5. Gorbach SL, Edelman R. Travelers’ diarrhea: National Institutes of Health Consensus Development Conference. Bethesda, Maryland, January 28–30, 1985. Rev Infect Dis. 1986 May–Jun;8 Suppl 2:S109–233.
  6. Gorbach SL, Kean BH, Evans DG, Evans DJ, Jr., Bessudo D. Travelers’ diarrhea and toxigenic Escherichia coli. N Engl J Med. 1975 May 1;292(18):933–6.
  7. Kean BH, Waters SR. The diarrhea of travelers. III. Drug prophylaxis in Mexico. N Engl J Med. 1959 Jul 9;261(2):71–4.
  8. Kuschner RA, Trofa AF, Thomas RJ, Hoge CW, Pitarangsi C, Amato S, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis. 1995 Sep;21(3):536–41.
  9. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004 Sep;99(9):1774–8.
  10. Ouyang-Latimer J, Jafri S, VanTassel A, Jiang ZD, Gurleen K, Rodriguez S, et al. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother. 2011 Feb;55(2):874–8.
  11. Owen JR. Diarrhoea at the Olympics. Br Med J. 1968 Dec 7;4(5631):645.
  12. Petruccelli BP, Murphy GS, Sanchez JL, Walz S, DeFraites R, Gelnett J, et al. Treatment of traveler’s diarrhea with ciprofloxacin and loperamide. J Infect Dis. 1992 Mar;165(3):557–60.
  13. Rowe B, Taylor J, Bettelheim KA. An investigation of traveller’s diarrhoea. Lancet. 1970 Jan 3;1(7636):1–5.
  14. Steffen R. Epidemiologic studies of travelers’ diarrhea, severe gastrointestinal infections, and cholera. Rev Infect Dis. 1986 May–Jun;8 Suppl 2:S122–30.
  15. Steffen R, van der Linde F, Gyr K, Schar M. Epidemiology of diarrhea in travelers. JAMA. 1983 Mar 4;249(9):1176–80.
  16. Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler’s diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis. 2006 Oct 1;43(7):898–901.
  17. Tribble DR, Sanders JW, Pang LW, Mason C, Pitarangsi C, Baqar S, et al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007 Feb 1;44(3):338–46.
  18. Wistrom J, Jertborn M, Hedstrom SA, Alestig K, Englund G, Jellheden B, et al. Short-term self-treatment of travellers’ diarrhoea with norfloxacin: a placebo-controlled study. J Antimicrob Chemother. 1989 Jun;23(6):905–13.